New hope for rare eye cancer: drug trial aims to wipe out liver tumors before surgery
NCT ID NCT07057596
Summary
This study is testing a drug called tebentafusp in patients with a rare eye cancer (uveal melanoma) that has spread only to the liver. The goal is to see if giving the drug for six months before surgery can completely eliminate the cancer in the liver and help keep it from coming back. The trial will enroll 19 patients who have not had prior treatment for their spread of cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MESTASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Charité - Universitätsmedizin Berlin
RECRUITINGBerlin, State of Berlin, 10117, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Consorcio Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, 46014, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital La Paz
RECRUITINGMadrid, Madrid, 28046, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Institut Catala d'Oncologia (ICO) Hospitalet
NOT_YET_RECRUITINGL'Hospitalet de Llobregat, Barcelona, 08908, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.